Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304910 · ClinicalTrials.gov registry record · Phase 1
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
A Phase 1 study of Migraine, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT05304910 is a Phase 1 study of Migraine that has completed, run by H. Lundbeck A/S. The registered enrollment target is 52 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05304910, a Phase 1 study of Migraine, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of the study is to learn more about how the body absorbs and eliminates Lu AG09222 after a single dose is injected under the skin. Researchers will also investigate safety and tolerability effects of Lu AG09222 after administration.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lu AG09222
Study Locations (1)
California
- PAREXEL International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-03-18 |
| Est. Completion | 2022-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05304910
The ClinicalTrials.gov registry entry for NCT05304910 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (85% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05304910 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05304910 about?
NCT05304910 is a clinical study titled "A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants". The main goal of the study is to learn more about how the body absorbs and eliminates Lu AG09222 after a single dose is injected under the skin. Researchers will also investigate safety and tolerability effects of Lu AG09222 after administration.
What is the current status of trial NCT05304910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2022-03-18. Estimated completion is 2022-10-30.
What conditions does trial NCT05304910 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05304910?
The interventions under investigation include: Placebo (DRUG), Lu AG09222 (DRUG).
Who is sponsoring clinical trial NCT05304910?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05304910 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.